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doi:10.1Objective: Patients recovering from cardiothoracic surgery are known to be at increased risk of heparin-induced
thrombocytopenia. Postoperatively, if heparin-induced thrombocytopenia is suspected, heparin is discontinued
immediately and an alternative anticoagulant, such as the direct thrombin inhibitor argatroban, is administered.
Current data regarding the safety and efficacy of argatroban in the postoperative cardiothoracic surgical patient
in the intensive care setting are limited.
Methods:Data were collected retrospectively from January 1, 2007, to December 31, 2010, from patients tested
for antiplatelet factor 4/heparin antibodies on clinical suspicion of heparin-induced thrombocytopenia after car-
diothoracic surgery. We evaluated the use of argatroban as a therapeutic agent for the postoperative treatment of
suspected heparin-induced thrombocytopenia by comparing thrombotic and bleeding events, platelet dynamics,
antiplatelet factor 4/heparin antibody titer, and clinical probability score between patients who did and did not
receive argatroban.
Results: Eighty-seven patients were included; 47 patients (54%) were treated with argatroban, and 40 patients
(46%) were not treated with argatroban. There was no association between argatroban therapy and bleeding,
mortality, length of stay, or pretreatment thrombotic events. Among all patients, antiplatelet factor 4/heparin an-
tibody titer and clinical probability score were higher in patients treated with argatroban.
Conclusions: Clinical suspicion of heparin-induced thrombocytopenia as detected by clinical probability score
and thrombotic complications should prompt immediate cessation of heparin and initiation of an alternative an-
ticoagulant such as argatroban. The results from this study demonstrate that argatroban should be considered
without increased risk for adverse events, including bleeding, in the cardiothoracic intensive care unit after
surgery. (J Thorac Cardiovasc Surg 2012;143:1213-8)Patients undergoing cardiothoracic surgery routinely receive
large doses of unfractionated heparin during their procedure.
Platelet activation during surgery and cardiopulmonary
bypass (CPB) likely confers an increased risk for postopera-
tive heparin-induced thrombocytopenia (HIT), which occurs
in 1% to 3% of these patients.1-3 Patients who develop HIT
antibodies, antibodies that recognize multimeric platelet
factor 4 (PF4)/heparin complexes on platelet surfaces, are
considered to be in a procoagulant state and at high risk for
adverse thrombotic complications.4 Heparin-induced throm-
bocytopenia with thrombosis (HITT) is the clinical syn-
drome in which patients with HIT antibodies develop
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Mischemia, or deep vein thromboses (DVTs) secondary to
HIT.5-7 Postoperatively, if HIT is suspected, heparin is
discontinued immediately and an alternative anticoagulant
such as the direct thrombin inhibitor (DTI) argatroban is
administered, either as a prophylactic anticoagulant or for
the treatment of thrombosis in patients with HITT.8 There
is a high index of suspicion for HIT in the cardiothoracic
intensive care unit (ICU) because of evidence that this
patient population is at increased risk of HITT.
Argatroban’s advantage in a critically ill patient is that it
has a relatively short half-life and is generally not affected
by renal dysfunction, gender, or age.9,10 The anticoagulant
effects of argatroban are monitored by measuring the
activated partial thromboplastin time (aPTT), which
increases in a dose-dependent manner, parallel to the levels
of argatroban.11 The argatroban dose is adjusted to achieve
an aPTT of 60 to 80 seconds or an aPTT of 1.5 to 3 times
the patient’s baseline aPTT.12,13 It is standard practice in
our cardiothoracic ICU to begin argatroban at first clinical
suspicion of HIT based on rapid decline or persistently low
platelet counts (Dp) postoperatively. Argatroban is begun
immediately on suspicion of HIT and continued if a PF4/
heparin immunoassay is positive; argatroban is typically
discontinued if the PF4/heparin immunoassay is negative.diovascular Surgery c Volume 143, Number 5 1213
Abbreviations and Acronyms
aPTT ¼ activated partial thromboplastin time
CPB ¼ cardiopulmonary bypass
DTI ¼ direct thrombin inhibitor
DVT ¼ deep vein thrombosis
ELISA ¼ enzyme-linked immunosorbent assay
HIT ¼ heparin-induced thrombocytopenia
HITT ¼ heparin-induced thrombocytopenia
with thrombosis
ICU ¼ intensive care unit
Ig ¼ immunoglobulin
OD ¼ optical density
Dp ¼ platelet count
PE ¼ pulmonary embolism
PF4 ¼ platelet factor 4
SRA ¼ serotonin release assay
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MBecause cardiac surgical patients are at potential risk for
bleeding and other adverse outcomes of postoperative antico-
agulation, it is important to maintain clinical suspicion for
HIT with the use of a standard pretest clinical probability
tool, recognize potential risks and benefits of argatroban ther-
apy in the cardiothoracic surgical patient population, and treat
with argatroban when indicated. Although there are previous
reports using argatroban as an anticoagulant, there is little in-
formation about its use postoperatively in the critical care set-
ting after cardiac surgery.14,15 We evaluated our experience
with argatroban as a therapeutic agent for the postoperative
treatment of suspected HIT in the cardiothoracic ICU. We
investigated thrombotic and bleeding events, laboratory
markers of HIT including platelet dynamics and PF4/
heparin immunoassay results, and clinical probability
scores in patients who did and did not receive argatroban.MATERIALS AND METHODS
Patients
After institutional approval, 3508 patients admitted to the cardiotho-
racic ICU after cardiothoracic surgery (cardiac cases, and heart and lung
transplants) from January 1, 2007, to December 31, 2010, were screened
for inclusion. Data were collected by retrospective medical chart review
from patients who had been tested for anti-PF4/heparin antibodies on clin-
ical suspicion of HITwithin 30 days after surgery. The clinical suspicion of
HIT was determined on the basis of a persistently low or rapid decline in
Dp, or new evidence of thrombosis after surgery.
HIT antibody testing was performed by the Special Hemostasis Labora-
tory at Emory University Hospital. Plasma samples from January 2007 to
August 2009were testedusing a commercial enzyme-linked immunosorbent
assay (ELISA) for antibodies of immunoglobulin (Ig)-G, IgA, and IgM clas-
ses (PF4 Enhanced; GTI Diagnostics, Waukesha, Wis) as previously
described.16 Plasma samples collected from September 2009 to Decem-
ber2010 were tested using a commercial ELISA specific for IgG antibodies
(Zymutest HIA IgG; HYPHENBioMed, Aniara,Mason, Ohio). For both as-
says, results were expressed in optical density (OD) units; a value of 0.4 or
greater was considered positive because the negative predictive value for1214 The Journal of Thoracic and Cardiovascular SurOD less than 0.4 in both assays is known to be 100%.17 When possible,
the serotonin release assay (SRA), which is currently considered the gold
standard for the laboratory diagnosis of HIT, was performed on samples
demonstrating an OD of 0.4 or greater by a designated reference laboratory
at the discretion of the ordering physician. A result of 20% or greater
serotonin release was reported as positive by the reference laboratory.
The indication for anticoagulation in patients with suspected HIT was
a thrombotic complication, rapid decline, or persistently lowDp.Argatroban
was initiated as a continuous infusion of 1.5mg/kg/min for patients with nor-
mal liver function. A reduced dose of 0.5 mg/kg/min was used if the patient
had liver dysfunction, defined as a Child–Pugh score greater than 7.18 Per
protocol, the aPTTwas measured 2 hours after the start of the argatroban in-
fusion, and dose adjustments were made to maintain desired aPTT levels
(1.5–3 times baseline, not to exceed 100 seconds). The aPTTwas assessed
4 hours after any dose adjustment or daily for patients with 2 or more thera-
peutic aPTT levels. Argatroban was avoided if patients were actively bleed-
ing or had evidence of acute stroke or other central nervous system process.
Patients were divided into 2 groups: those who received anticoagulation
with argatroban and those who did not. Patients who did not receive arga-
troban received heparin subcutaneously for DVT prophylaxis or intrave-
nously for a specific anticoagulation indication (eg, history of PE, DVT,
valve surgery, or known hypercoagulable state without suspicion of
HIT). Anti-Xa levels were used for monitoring intravenous heparin therapy
with high- and low-dose titrations. In these patients, 3 to 5 titrations were
typically required. If patients were not receiving any anticoagulation, me-
chanical methods of DVT prophylaxis were used.
Detailed data were collected on age, gender, date of admission and dis-
charge, date and cause of death if applicable, number of doses of argatroban
received, surgery date and type, use of CPB, baseline Dp before surgery,
daily Dp when available from 2 days before surgery to 30 days post-
surgery, and PF4/heparinOD.The postoperative decrease inDpwas defined
as the percent decline in platelets from the platelet peak attained postoper-
atively to the subsequent platelet nadir. Data on adverse outcomeswere also
collected, including occurrence of thrombotic complications (defined as
DVT, myocardial infarction, embolic cerebrovascular accident, PE, or
limb ischemia), mortality, length of stay, and bleeding complications.
The clinical features of HIT were quantified using the 4Ts score as de-
scribed previously.19 Briefly, the 4 ‘‘Ts’’ in the 4Ts score are (1) thrombo-
cytopenia with a Dp decrease greater than 50% and platelet nadir of 20;
(2) timing of platelet fall with clear onset between days 5 and 10 or platelet
decrease 1 day (prior heparin exposure within 30 days); (3) new throm-
bosis (confirmed); and (4) no other likely cause for thrombocytopenia.19
The resulting clinical probability scores are divided into high (6–8 points),
intermediate (4–5 points), and low (3 points) groups. In addition, the
platelet profiles were categorized as P1, platelet decline greater than
50% from a postoperative maximum within 5 to 10 days after surgery,
or P2, persistent thrombocytopenia beyond 5 days after surgery based on
the platelet profiles described by Pouplard and colleagues.20
Statistical Analyses
Patients were divided into 2 groups: those treated with argatroban and
those not treated with argatroban. Mean values for length of stay; baseline,
minimum, and maximumDp; and PF4/heparin OD were compared between
the 2 groups using the Mann–WhitneyU test. Categoric variables, including
the incidence ofmortality, bleeding, thrombotic complications, on-pump sur-
gery, and occurrence of each platelet profile, were compared between the 2
groups with the Fisher exact test (for dichotomous variables). All statistical
analyses were performed using SPSS statistics 19.0 (SPSS Inc, Chicago, Ill).RESULTS
Patients
Eighty-seven patients with an anti-PF4/heparin antibody
test conducted within 30 days after cardiothoracic surgerygery c May 2012
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diothoracic ICU were included in this study. Forty-seven
patients (54%) were treated with argatroban, and 40 pa-
tients (46%) were not treated with argatroban. Among all
patients, 38 (46%) had a platelet decline greater than
50% from a postoperative maximum within 10 days after
surgery consistent with the P1 platelet profile, and 21 pa-
tients had persistent thrombocytopenia beyond 5 days after
surgery consistent with the P2 profile. The median 4Ts
score for all patients was 3 (range, 0–7; interquartile
range, 1–5).
Among 47 patients treated with argatroban, median 4Ts
score was 4 (range, 0–7; interquartile range, 2–5), 22 had
a P1 platelet profile, and 15 had a P2 profile. Mean PF4/hep-
arin OD was 1.012 (range, 0.104–3.000). Six patients had
a high 4Ts score, 23 patients had an intermediate 4Ts score,
and 18 patients had a low 4Ts score. Thirty-seven (79%) of
the 47 patients treated with argatroban had a positive PF4/
heparin ELISA (OD>0.4). Of the 10 patients with a nega-
tive PF4/heparin ELISA, 5 received only 1 day of treatment
with argatroban before it was discontinued when the result
of the PF4/heparin ELISAwas negative. Five patients with
a negative PF4/heparin ELISA continued taking argatroban
at the physician’s discretion because of a need for continued
anticoagulation (history of DVT, PE, limb ischemia, or
known hypercoagulable state). SRA was positive in 7 of
the 22 patients whose samples were sent for SRA testing.
Recovery ofDp after argatroban was variable; no specific
pattern of platelet recovery was seen in either treatment
group, likely because of all of the different factors that de-
termine postoperative thrombocytopenia after cardiac sur-
gery. In 32 patients (68%), there were transient aPTT
values greater than 100 seconds after argatroban was initi-
ated, but all elevated aPTT values resolved with appropriate
titration.
Of the 40 patients not treated with argatroban, median
4Ts score was 2 (range, 0–6), 16 had a P1 profile, and 6
had a P2 profile. Thirteen (33%) of the 40 patients had
a PF4/heparin OD greater than 0.40 (mean, 0.354; range,
0.031–2.365). One patient had a high 4Ts score, 8 patients
had an intermediate 4Ts score, and 31 patients had a low
4Ts score. Seven total samples were sent for SRA testing
and 6 were negative, likely the explanation for lack of arga-
troban initiation. Subcutaneous heparin was withdrawn in
the patient with a positive SRA, and alternative anticoagu-
lation was not begun. Of the 13 patients with a positive PF4/
heparin ELISA, subcutaneous heparin for DVT prophylaxis
or intravenous heparin for anticoagulation was continued in
those who had a negative SRA (n ¼ 6), patients were
switched from subcutaneous heparin for DVT prophylaxis
to enoxaparin or fondaparinux (n ¼ 4), or all heparin was
discontinued (n ¼ 3). Intravenous heparin was given in 8
of the 40 patients who did not receive argatroban in re-
sponse to a continued need for intravenous coagulation;The Journal of Thoracic and Carall of these patients had a negative PF4/heparin ELISA or
SRA.Complications
Among the 47 patients treated with argatroban, 11 (26%)
died and 3 (6%) had bleeding complications. Two patients
had gastrointestinal bleeds likely secondary to peptic ulcer
more than 3 weeks after argatroban therapy; 1 patient had
epistaxis, hypotension, and oxygen desaturation approxi-
mately 2 days after argatroban therapy and died of respira-
tory failure. In this patient, aPTT had returned to normal,
suggesting death was unrelated to argatroban. Among the
11 argatroban-treated patients who died, cause of death
was determined to be respiratory failure and oxygen
desaturation (n¼ 2), multiorgan system failure (n¼ 7), dis-
seminated intravascular coagulation (n ¼ 1), and cerebro-
vascular accident with myocardial infarction (n ¼ 1).
None of the patients who died were receiving argatroban
at the time of death. Of 20 total thrombotic complications,
the thrombotic event was the clinical sign that prompted
HIT testing and argatroban initiation in 15 patients. The re-
maining 5 additional thrombotic complications occurred
despite argatroban.
Among the 40 patients not treated with argatroban, 8
(20%) died and 5 (13%) had bleeding complications.
Among the 5 patients with bleeding complications that
were not treated with argatroban, 1 patient was receiving
heparin intravenously for a known hypercoagulable state
and 4 patients were receiving heparin (n ¼ 3) or fondapar-
inux (n ¼ 2) subcutaneously for DVT prophylaxis. Six pa-
tients who did not receive argatroban had a thrombotic
complication, including 2 who subsequently had a positive
PF4/heparin ELISA; although argatroban was not initiated
in these patients, all heparin was discontinued immediately.Comparisons Between Groups
Table 1 shows comparisons between the argatroban-
treated and non–argatroban-treated groups. PF4/heparin
OD was significantly greater in patients who received arga-
troban (P<.001). There were no significant differences ob-
served between the groups for Dp; baseline, maximum, or
minimum Dp; and length of stay. Patients treated with arga-
troban were more likely to have a high 4Ts score (P ¼ .02).
There were no significant differences between groups for
age, gender, mortality, use of CPB, or bleeding complica-
tions. Thrombotic complications before initiation of arga-
troban were more likely to occur in patients eventually
anticoagulated with argatroban compared with those not
treated with argatroban. In a separate comparison, patients
treated with intravenous heparin anticoagulation (n ¼ 8)
demonstrated no differences with respect to mortality,
bleeding, or thrombotic events compared with those treated
with argatroban.diovascular Surgery c Volume 143, Number 5 1215
TABLE 1. Characteristics, complications, and laboratory values in
cardiothoracic surgical patients in the intensive care unit treated or
not treated with argatroban
Argatroban-
treated
(N ¼ 47)
Non–argatroban-
treated
(N ¼ 40)
PF4/heparin immunoassay
OD>0.40 (%)
37 (79%) 13 (33%)
Mean PF4/heparin OD
(range)
1.012
(0.104–3.000)*
0.354 (0.031–2.365)
No. with P1 profile (%) 22 (47%) 16 (40%)
No. with P2 profile (%) 15 (32%) 6 (15%)
Dp (range) 59 (2–98) 46 (0–88)
Minimum Dp (range) 63 (4–223) 67 (17–241)
Maximum Dp (range) 165 (80–394) 125 (60–324)
Median 4Ts score (range,
interquartile range)y
4 (0–7, 2–5) 2 (0–6, 0–3)
High (6) 4Ts score 6 (13%) 1 (3%)
Intermediate (4–5) 4Ts
score
23 (49%) 8 (20%)
Low (3) 4Ts score 18 (38%) 31 (78%)
SRA positive (% of total
SRA tests done)
7/22 (32%) 1/7 (14%)
Thrombotic complications
before argatroban initiated
15 (32%)* 6 (15%)
Bleeding complications 3 (6%) 5 (13%)
Thrombotic complications
after argatroban initiation
5 n/a
No. with on-pump surgery 31 (66%) 27 (68%)
Mortality 11 (23%) 8 (20%)
Length of stay in days (range) 38 (10–144) 29 (6–165)
The percentage of patients in each treatment category is shown. Thrombotic compli-
cations are defined as embolic cerebral vascular accident, DVT, PE, myocardial in-
farction, or limb ischemia. *Significant at P < .01. y4Ts score is significantly
greater in patients treated with argatroban by chi-square test (P ¼ .023).
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In patients admitted to the cardiothoracic ICU after car-
diothoracic surgery, the use of argatroban was not associ-
ated with bleeding complications. This is important
because patients in an ICU setting after cardiothoracic sur-
gery may be at risk for complications due to bleeding. We
believe that argatroban is safe after cardiothoracic surgery
because of the relatively short half-life, lack of adverse ef-
fects on platelets, and clearance independent of renal func-
tion. Argatroban is a potent anticoagulation agent, and the
lack of increased bleeding complications in patients treated
with argatroban is encouraging, with its rapid clearance per-
haps important in its safety.21 Because we found no in-
creased rate of bleeding, mortality, or length of stay in our
patients treated with argatroban, the initiation of argatroban
therapy immediately on suspicion of HIT should not be de-
layed, a conclusion consistent with American College of
Chest Physicians guidelines.22
A greater likelihood of high 4Ts score among argatroban-
treated patients suggests that the clinical 4Ts score, which1216 The Journal of Thoracic and Cardiovascular Surquantifies thrombocytopenia, platelet dynamics, and throm-
botic complications, is used by clinicians in determining
whether a PF4/heparin ELISA test should be sent and
whether argatroban therapy should be initiated. Thrombocy-
topenia during the first 4 postoperative days is rarely attribut-
able to HIT because heparin administered during surgery
usually does not induce significant levels of HIT antibodies
until postoperative day 5 or later.23,24 However, it is evident
from our study that treating physicians use the clinical 4Ts
score to some extent in guiding diagnosis and treatment of
HIT, although perhaps not explicitly. Of note, PF4/heparin
OD and the incidence of thrombotic complications were
significantly greater in patients treated with argatroban,
suggesting that clinical suspicion for HIT in our
cardiothoracic ICU is relatively appropriate in guiding
argatroban initiation. For patients who had a low 4Ts score
and neither P1 nor P2 platelet profile, we were unable to
determine the clinical reasoning for sending a PF4/heparin
ELISA. The decline of Dp between postoperative days
5-10 is a marker of platelet consumption resulting from
antibodies that develop after cardiothoracic surgery and
recognize multimeric PF4/heparin complexes on platelet
surfaces.20,24 Although there was no association between
Dp and argatroban treatment, Dp is a major component of
the 4Ts scoring system, and as such this marker may be
a compelling indicator that HIT should be clinically
suspected and alternative anticoagulation begun without
waiting for PF4/heparin immunoassay results.20,22,25
A primary safety concern with argatroban and other anti-
coagulants is major bleeding. In the cardiothoracic ICU af-
ter cardiothoracic surgery, unfractionated heparin is always
the drug of choice because of short half-life, minimal effects
of renal dysfunction, and reversibility. Some of the patients
were receiving DVT prophylaxis with subcutaneous hepa-
rin; however, other indications for high- or low-dose intra-
venous anticoagulation included bridging for valve repair,
recent valvular surgery, recent thrombotic complication,
and a negative PF4/heparin ELISA result or history of
DVT or PE. Patients who were not anticoagulated were
thought to be at a higher risk for bleeding. Because the
argatroban-treated and non-treated patients had similar out-
comes in our study, one conclusion may be that argatroban
is safe after CPB, and another may be that anticoagulation is
not necessary. However, true HIT is rare, and specific risk
factors other than heparin exposure remain unknown; the
non-treated patients may not have been at higher risk for
HIT.
In prospective, multicenter studies not limited to cardio-
thoracic surgical patients, argatroban significantly im-
proved outcomes in HIT, particularly reducing new
thrombosis and mortality without increasing risk of bleed-
ing.12,13 In our study, it is unlikely that the bleeding
complications seen in argatroban-treated patients were the
result of argatroban itself because its half-life isgery c May 2012
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in all but 1 patient occurred at least 2 weeks after the cessa-
tion of argatroban, and all had a normal aPTT at the time of
bleeding. In addition, none of the patients developed bleed-
ing complications during the time period that argatroban
was being administered. Our study is consistent with a pre-
vious retrospective analysis of 31 cardiothoracic surgery
patients who received argatroban starting 1.7 days after sur-
gery at doses of 0.66 mg/kg/min over a median duration of
5.9 days.26 The investigators noted that no intracranial,
intra-abdominal, or retroperitoneal bleeding events were re-
ported in these patients and that no clear source of bleeding
was identified from imaging studies. It is interesting to note
that argatroban was approved without a randomized control
group because only historic controls were used in approval
of this drug.13 Thus, our study provides important addi-
tional evidence that early postoperative use of argatroban
is well tolerated and associated with a low risk of throm-
botic and bleeding events.
Study Limitations
There are several limitations to this study. First, because
of the data-collection methods, we were unable to deter-
mine the dose ranges, dose adjustments, and duration of ar-
gatroban infusions. In addition, we currently use anti-Xa
levels for monitoring heparin therapy with intravenous ad-
ministration and were therefore unable to compare aPTT
levels between argatroban-treated and non–argatroban-
treated patients. Second, argatroban was withheld from
some patients despite a positive PF4/heparin ELISA result,
presumably because of a concern for an increased risk of
bleeding. We did not have access to transfusion data and
were therefore unable to corroborate this presumption or
identify subclinical bleeding by quantifying transfusion re-
quirements in our patients as previous studies have done.14
Last, the small number of patients included and the retro-
spective nature of this study made it difficult to explicitly
evaluate safety. For these reasons, the actual efficacy of ar-
gatroban for the prevention of HIT and thrombotic compli-
cations cannot be determined from our data.
CONCLUSIONS
Standardized criteria, such as the 4Ts clinical scoring
system and platelet profiles, can be used to appropriately
initiate PF4/heparin antibody testing and immediately initi-
ate argatroban. Clinicians often delay initial anticoagulation
therapy on clinical suspicion of HIT because of safety con-
cerns about bleeding. The lack of increased risk for adverse
events with argatroban in the cardiothoracic ICU after sur-
gery suggests early therapy with argatroban as a DTI should
be considered. Other DTIs currently available for use in-
clude the parenteral agents lepirudin, desirudin, and bivalir-
udin, and the oral agent dabigatran. The results from our
study support argatroban use on immediate clinicalThe Journal of Thoracic and Carsuspicion of HIT as detected by an otherwise unexplained
decrease in Dp greater than 50% approximately 5 to 10
days postoperatively or thrombotic complications in all pa-
tients after cardiothoracic surgery and before confirmatory
laboratory results. Additional prospective, randomized
studies are needed to support our findings and to determine
the relative safety of argatroban and other DTIs.
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